ReActiv8-A Clinical Trial – Sustained Performance at One Year
Dublin, Ireland: 20 September 2016 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain ("CLBP"), today announced the one-year results from the ReActiv8-A Clinical Trial, an international, multi-centre, prospective, single arm trial for ReActiv8 in people with disabling CLBP and few other treatment options.
The one-year results show sustained performance in the ReActiv8-A Clinical Trial at the one-year follow-up with a clinically important, statistically significant and lasting improvement in the study's key endpoints for pain (NRS), disability (ODI) and quality of life (EQ-5D).
More info on Mainstay Medical's website.
Next > Leading sequencing service provider GATC Biotech adopts Bluebee for genomic analysis
Previous > FEops elects Rob Michiels as Chairman